Published in PLoS One on August 23, 2013
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study (APPRoAcH-p) | NCT03655704
Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov (2014) 3.54
CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell (2014) 1.45
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A (2014) 1.25
Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest (2014) 1.20
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget (2013) 1.17
Use of epigenetic drugs in disease: an overview. Genet Epigenet (2014) 1.08
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther Adv Hematol (2015) 1.06
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget (2015) 1.06
Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. J Biol Chem (2014) 1.01
Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer (2015) 1.01
A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis. Cancer Cell (2015) 0.97
Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11. Br J Pharmacol (2014) 0.94
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget (2015) 0.90
Directly targeting transcriptional dysregulation in cancer. Nat Rev Cancer (2015) 0.87
The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. Oncotarget (2016) 0.83
Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nat Chem Biol (2016) 0.83
BET inhibition as a new strategy for the treatment of gastric cancer. Oncotarget (2016) 0.81
Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review. World J Gastroenterol (2014) 0.81
The biology of castration-resistant prostate cancer. Curr Probl Cancer (2014) 0.80
Alternative modulation of protein-protein interactions by small molecules. Curr Opin Biotechnol (2015) 0.79
BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. ACS Med Chem Lett (2015) 0.79
BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene (2016) 0.76
Chromatin deregulation in disease. Chromosoma (2015) 0.76
Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma. Surgery (2015) 0.76
Epigenetics in cancer stem cells. Mol Cancer (2017) 0.75
MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development. PLoS One (2017) 0.75
Cell Proliferation in Neuroblastoma. Cancers (Basel) (2016) 0.75
MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells. Oncotarget (2016) 0.75
Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: A Computational Study. J Chem Theory Comput (2017) 0.75
A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers. Yale J Biol Med (2017) 0.75
The MYCN Protein in Health and Disease. Genes (Basel) (2017) 0.75
The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Oncotarget (2016) 0.75
Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A (2017) 0.75
Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-dominant Allergic Airway Disease. Sci Rep (2017) 0.75
BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). Oncotarget (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Translating the histone code. Science (2001) 56.77
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
GenePattern 2.0. Nat Genet (2006) 29.07
Selective inhibition of BET bromodomains. Nature (2010) 18.79
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Neuroblastoma. Lancet (2007) 10.61
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry (1983) 6.38
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
Cancer epigenetics reaches mainstream oncology. Nat Med (2011) 5.83
An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol (2003) 4.49
Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol Cell Biol (2007) 3.95
N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev (2000) 3.62
The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol (2006) 3.31
Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell (2009) 3.29
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell (2008) 3.05
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A (2012) 2.52
Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem (2011) 2.45
Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res (1991) 2.23
You bet-cha: a novel family of transcriptional regulators. Front Biosci (2001) 2.20
RING3 kinase transactivates promoters of cell cycle regulatory genes through E2F. Cell Growth Differ (2000) 2.13
MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res (2010) 2.00
Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res (2013) 1.84
Place your BETs: the therapeutic potential of bromodomains. Trends Pharmacol Sci (2012) 1.71
NUT midline carcinoma. Cancer Genet Cytogenet (2010) 1.64
Identification of transcription complexes that contain the double bromodomain protein Brd2 and chromatin remodeling machines. J Proteome Res (2006) 1.64
High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A (2008) 1.59
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A (2012) 1.46
Identification and characterization of BRDT: A testis-specific gene related to the bromodomain genes RING3 and Drosophila fsh. Genomics (1997) 1.43
Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol (1993) 1.42
Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res (1994) 1.32
Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol (1996) 1.19
Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther (2009) 1.18
DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res (2012) 1.17
Global genomic and proteomic analysis identifies biological pathways related to high-risk neuroblastoma. J Proteome Res (2010) 1.00
Differentiation and apoptosis of neuroblastoma cells: role of N-myc gene product. J Cell Biochem (1999) 0.98
IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma. Cell Death Differ (2000) 0.97
E2F proteins regulate MYCN expression in neuroblastomas. J Biol Chem (2002) 0.95
Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer (2003) 0.92
Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Biochem Biophys Res Commun (2011) 0.89
The N-myc and c-myc downstream pathways include the chromosome 17q genes nm23-H1 and nm23-H2. Oncogene (2002) 0.88
Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia (2001) 0.87
Functional homology between N-myc and c-myc in murine plasmacytomagenesis: plasmacytoma development in N-myc transgenic mice. Oncogene (1992) 0.86
Targeted BCL2 inhibition effectively inhibits neuroblastoma tumour growth. Eur J Cancer (2012) 0.83
Suppression of inflammation by a synthetic histone mimic. Nature (2010) 8.80
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell (2005) 7.65
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Natural mutagenesis of human genomes by endogenous retrotransposons. Cell (2010) 5.50
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis (2008) 3.84
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A (2012) 3.22
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell (2006) 3.08
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol (2008) 2.85
Chromatin proteins and modifications as drug targets. Nature (2013) 2.60
Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol Cell (2013) 2.55
Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem (2011) 2.45
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther (2012) 2.21
Suppression of the antiviral response by an influenza histone mimic. Nature (2012) 2.18
Zygote arrest 1 (Zar1) is a novel maternal-effect gene critical for the oocyte-to-embryo transition. Nat Genet (2003) 2.09
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J Med Chem (2013) 2.09
Lysine methylation of the NF-κB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-κB signaling. Nat Immunol (2010) 2.07
Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase. Biochem J (2008) 1.79
Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A (2010) 1.72
MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia (2002) 1.71
Systems biology and the host response to viral infection. Nat Biotechnol (2007) 1.53
Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Cancer Res (2009) 1.53
Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J Med Chem (2012) 1.42
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase. J Med Chem (2008) 1.41
ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol (2007) 1.39
Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors. Proc Natl Acad Sci U S A (2012) 1.39
A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues. Proc Natl Acad Sci U S A (2006) 1.38
Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability. Mol Cell Biol (2008) 1.37
Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J Exp Med (2012) 1.36
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res (2008) 1.33
Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens. J Biomol Screen (2012) 1.30
The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism. J Biol Chem (2005) 1.30
GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models. Mol Cancer Ther (2009) 1.27
GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther (2009) 1.25
Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett (2012) 1.24
Cancer epigenetics drug discovery and development: the challenge of hitting the mark. J Clin Invest (2014) 1.20
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood (2013) 1.20
Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics (2012) 1.19
Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors. J Am Chem Soc (2002) 1.18
Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1. Cancer Res (2004) 1.18
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget (2013) 1.17
Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. J Biol Chem (2003) 1.15
Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase. Clin Cancer Res (2009) 1.14
Evidence for allosteric interactions of antagonist binding to the smoothened receptor. J Pharmacol Exp Ther (2009) 1.13
A second p53 binding site in the central domain of Mdm2 is essential for p53 ubiquitination. Biochemistry (2006) 1.13
Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery. BMC Evol Biol (2011) 1.12
Binding of TPX2 to Aurora A alters substrate and inhibitor interactions. Biochemistry (2007) 1.12
From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci (2004) 1.09
3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase. J Med Chem (2006) 1.09
Enzymatic characterization of the pancreatic islet-specific glucose-6-phosphatase-related protein (IGRP). J Biol Chem (2004) 1.06
Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol (2005) 1.05
Abeta(1-42) reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: a quantitative analysis. J Neurosci Methods (2008) 1.04
Mice deficient in oocyte-specific oligoadenylate synthetase-like protein OAS1D display reduced fertility. Mol Cell Biol (2005) 1.04
Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition. Biochemistry (2004) 1.04
Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy. Mol Cancer Res (2010) 1.04
The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem Biol (2013) 1.04
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) (2011) 1.03
Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc Natl Acad Sci U S A (2002) 1.03
Research Resource: The androgen receptor modulates expression of genes with critical roles in muscle development and function. Mol Endocrinol (2010) 1.03
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS One (2013) 1.02
5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res (2007) 1.02
Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res Commun (2011) 1.01
Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary (2008) 1.00
An assay for Fe(II)/2-oxoglutarate-dependent dioxygenases by enzyme-coupled detection of succinate formation. Anal Biochem (2006) 1.00
Biochemical characterization of GSK1070916, a potent and selective inhibitor of Aurora B and Aurora C kinases with an extremely long residence time1. Biochem J (2009) 0.98
Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol (2012) 0.97
Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem (2007) 0.96
SCF Fbx4/alphaB-crystallin cyclin D1 ubiquitin ligase: a license to destroy. Cell Div (2007) 0.96